The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS
Jayastu Senapati, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents updates from a Phase II trial (NCT03672539) investigating CPX-351 in combination with gemtuzumab ozogamicin (GO) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and post-hypomethylating agent failure high-risk myelodysplastic syndromes (HR-MDS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
